Propanc Biopharma Inc (PPCB)

[swamp-rat]

Propanc Biopharma Inc.

James Nathanielsz, Propanc Biopharma Inc.

Propanc Biopharma is a biopharmaceutical company developing new cancer treatments for solid tumors. The company has developed a formulation of anti-cancer compounds designed to control or prevent tumors from recurring and spreading throughout the body by using proenzymes, which are inactive precursors of enzymes.

Date:Tuesday, February 12
Time:9:45 AM - 10:00 AM
Room:Hudson/Empire
Location:7th Floor
Session Type:Company Presentation
Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
Company HQ City:Camberwell
Main Therapeutic Focus:Oncology
Company Presentation - Presentation Type:Publicly Traded Company
Year Founded:2007
Submission ID:23328
Ticker:PPCB
CEO/Top Company Official:James Nathanielsz
Market Cap:$5.86 million
Lead Product in Development:PRP (trypsinogen/chymotrypsinogen I.V injection)
Company HQ Country:Australia
Development Phase of Primary Product:Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):1
Company Website:www.propanc.com
Exchange:OTCQB
Additional Information/Comments:Our lead product, PRP, is a solution for intravenous administration of a combination of two pancreatic proenzymes, trypsinogen and chymotrypsinogen. PRP prevents tumor recurrence and metastasis from solid tumors. PRP's unique patented approach is designed to target and eradicate cancer stem cells that are not killed by standard treatments. We recently completed preclinical development and are currently undertaking IMP manufacture to commence first-in-human studies in 2019. PRP received Orphan Drug Designation Status from the FDA for the treatment of pancreatic cancer. The company has joint research partnerships with Granada and Jaen Universities, as well as University Hospital in Granada, Spain, known as the Public Health Foundation Network, or FIBAO. The company has raised approx. $18 million and recently entered into a $10 million financing facility with an accredited institutional investor to fund future clinical development activities for our lead product, PRP.
Goal for Presentation:To inform life sciences investors regarding the exciting potential of our breakthrough technology.

Speakers

James Nathanielsz